UniversitÄt Bayreuth

Charité – Universitätsmedizin Berlin

Martin-Luther-Universität Halle-Wittenberg

Rainer Schobert

Bernhard Max Biersack

Michael Höpfner

Thomas Müller

Oxana Kempf

Elisa Bombarda

Karl Kempf

Katharina Mahal

G Matthias Ullmann

The present invention relates to a 4,5-diarylimidazole derivative of formulae (I), (II) or (III): or a pharmaceutically acceptable salt thereof, wherein the 4,5-diarylimidazole derivative has a hydroxamic acid residue at a first aryl ring and a residue R1 at a second aryl ring; and wherein R1 is hydrogen, a halogen atom or an unsubstituted or substituted alkoxy group; R2 is independently selected from an unsubstituted or substituted alkyl, alkoxy or alkene group; M is a metal atom; L is a halogen atom, an unsubstituted or substituted phosphane, sulfane, arene or alkene group or a 4,5-diarylimidazole-derivative of formula (I); and n is an integer of from 1 to 5. 

4,5-diarylimidazole derivatives as HDAC inhibitors

A new azobenzene-based fluorescence quencher with excellent solubility in aqueous solution is described here. This compound represents an optimized alternative to dabcyl in a variety of biomolecular applications, like fluorogenic protease substrates or nucleic acids probes.

Hydrodabcyl

The present invention relates to specific analogs of combretastatin, in particular the compounds of formula (I) as described and defined herein, and pharmaceutical compositions comprising the compounds, as well as their medical use, in particular in the treatment or prevention of cancer, including multidrug-resistant cancer. 

Combretastatin analogs for use in the treatment of cancer

Growing community of inventors

Bayreuth, Germany

Rainer Schobert